Blackstone Inc’s Vir Biotechnology VIR Stock Holding History

Blackstone Inc’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,000	Closed	-$440K	–	94
2019 Q4	$440K	Buy	+35,000	New	+$469K	﹤0.01%	65

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Blackstone Inc's VIR Position: Q1 2020 in Review

Blackstone Inc sold out of Vir Biotechnology (VIR) in Q1 2020, closing a stake of 35,000 shares — an estimated $440K sold.

Blackstone Inc first reported a position in VIR in Q4 2019 and held it in 1 quarter. The position peaked at $440K in Q4 2019. 61 funds tracked by Wall St. Rank hold VIR as of Q1 2020.

Blackstone Inc reported no remaining Vir Biotechnology position as of Q1 2020 after selling out during the quarter.
Blackstone Inc sold 35,000 Vir Biotechnology shares in Q1 2020, an estimated $440K.
Blackstone Inc first reported a position in Vir Biotechnology in Q4 2019 and held it in 1 quarter.
Blackstone Inc's Vir Biotechnology position peaked at $440K in Q4 2019.
61 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2020.

Based on Blackstone Inc's 13F filing for Q1 2020, filed 15 May 2020.